Clinical trials: HIV -1 Infection
HIV-1
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of…
- Trial name
- MODERN (NCT01345630)
- Testing
- Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg
- Where
- 177 sites in United States, Australia and 17 more
- Volunteers
- 813 people
- Sponsor
- ViiV Healthcare
HIV-1 Infections
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibotec Pharmaceuticals and continue to…
- Trial name
- NCT01138605
- Testing
- Darunavir, Ritonavir
- Where
- 13 sites in Argentina, Brazil and 6 more
- Volunteers
- 46 people
- Sponsor
- Janssen Sciences Ireland UC
Infection, Human Immunodeficiency Virus I, HIV Infection
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
The aim of this study was to assess whether TRIZIVIR, administered twice-daily was as safe, tolerable and efficacious as a combination of the drugs COMBIVIR administered twice-daily and atazanavir administered once daily.
- Trial name
- NCT00082394
- Testing
- Trizivir, atazanavir, Combivir
- Where
- 45 sites in United States, Mexico
- Sponsor
- GlaxoSmithKline
HIV Infections
A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients
The purpose of this study is to see if it is safe and effective to give an experimental anti-HIV drug, adefovir dipivoxil (ADV), in combination with other anti-HIV drugs (HAART) to patients who have a viral load (level of HIV in…
- Trial name
- NCT00002426
- Testing
- Adefovir dipivoxil
- Where
- 49 sites in United States, Canada and 3 more
- Volunteers
- 390 people
- Sponsor
- Gilead Sciences
HIV Infections
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
To evaluate, in HIV-infected patients whose baseline CD4 count is 300 to 750 cells/mm3, whether an antiretroviral treatment regimen based upon clinical evaluation and CD4 counts plus HIV RNA viral load is more effective than a…
- Trial name
- NCT00002376
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants.
- Trial name
- NCT00326716
- Testing
- Atazanavir + Ritonavir + Combivir
- Where
- 6 sites in United States, Puerto Rico and 1 more
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
HIV Infection
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
The main objective of this study is to compare the safety and efficacy of an enfuvirtide containing regimen to a nucleoside combination regimen. Resistance information will also be collected.
- Trial name
- NCT00100984
- Testing
- FUZEON [enfuvirtide]
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant…
- Trial name
- NCT04927585
- Testing
- env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Worcester HIV Vaccine
HIV Infections
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults.
- Trial name
- NCT04871113
- Testing
- GSK3810109A, Dolutegravir+lamivudine SOC regimen
- Where
- 24 sites in United States, Argentina and 4 more
- Volunteers
- 62 people
- Sponsor
- ViiV Healthcare
HIV Infections
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
- Trial name
- NCT02362503
- Testing
- BMS-663068
- Where
- 139 sites in United States, Argentina and 23 more
- Volunteers
- 371 people
- Sponsor
- ViiV Healthcare
HIV Infections, HIV Seronegativity
Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV.
- Trial name
- NCT00002441
- Testing
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- Where
- 67 sites in United States, Canada and 2 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- VaxGen
Human Immunodeficiency Virus Type 1 (HIV-1)
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the…
- Trial name
- NCT05896761
- Testing
- Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Where
- 32 sites in United States, Argentina and 5 more
- Volunteers
- 118 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs.
- Trial name
- NCT00002239
- Testing
- Enfuvirtide, Ritonavir, Abacavir sulfate
- Where
- 20 sites in United States
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
The use of a Bioject 2000 needle free injection device (NFID) and a compressed immunization schedule will be safely tolerated and will augment the immunogenicity of the HIV-1 CTL epitope DNA vaccine (EP1090) in HIV-1 infected…
- Trial name
- EP1090 (NCT00532974)
- Testing
- EP1090
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epimmune
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Efavirenz
GSK1349572 is an integrase inhibitor that is currently in Phase 2 clinical trials for the treatment of HIV infection. As GSK1349572 development progresses, it may be dosed with non-nucleoside HIV reverse transcriptase inhibitors…
- Trial name
- NCT01098526
- Testing
- GSK1349572, Efavirenz
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis C
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve…
- Trial name
- NCT01467479
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
- Where
- 59 sites in United States, Canada and 3 more
- Volunteers
- 185 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
HIV Infections
Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid
This protocol is intended to test the feasibility of using the HIV 1/2 STAT-PAK and the DPP HIV 1/2 test (with and without the DPP Handheld Reader) to detect HIV antibodies in oral fluids.
- Trial name
- HIVOF (NCT00636220)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Chembio Diagnostic Systems, Inc.
HIV Infections, Peripheral Nervous System Disease
Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS
To compare the effects of intranasal peptide T and placebo in the treatment of painful peripheral neuropathy associated with human immunodeficiency virus (HIV) infection.
- Trial name
- NCT00002083
- Testing
- Peptide T
- Where
- 4 sites in United States
- Sponsor
- Advanced Peptides
HIV, HIV Infection
Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
This research study is being carried out to study a new way to possibly treat human immunodeficiency virus (HIV). The agent is called SB-728-T which are CD4+ T-cells obtained from an individual that are genetically modified at…
- Trial name
- NCT01252641
- Testing
- SB-728-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sangamo Therapeutics
HIV Infections, Human Immunodeficiency Virus
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
The study will compare the safety and efficacy of an investigation nucleoside analog reverse transcriptase inhibitor (NRTI), dexelvucitabine (DFC), to an approved NRTI, lamivudine (3TC) in HIV treatment-experienced patients who…
- Trial name
- DECLARE (NCT00300573)
- Testing
- Dexelvucitabine
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation